Investor Presentaiton slide image

Investor Presentaiton

Investor presentation First three months of 2017 Slide 62 Key Novo Nordisk diabetes care products remain broadly available in the US Value market shares of key Novo Nordisk products in the US Value market share VictozaⓇ TresibaⓇ NovoLogⓇ % unrestricted market access of key Novo Nordisk products in the US VictozaⓇ TresibaⓇ NovoLogⓇ LevemirⓇ 80% 60% 40% 20% 0% Jan 2014 Source: IMS NSP February 2017; LevemirⓇ Unrestricted Market access 100% 80% 60% 40% 20% 0% Feb 2017 Note: Market shares: NovoLogⓇ: share of rapid acting insulin segment; LevemirⓇ: share of basal insulin segment; TresibaⓇ share of basal insulin segment; VictozaⓇ: share of GLP-1 segment changing diabetes Jan 2014 Source FingerTip Formulary bridge/ January 2017 Nomenclature and Xponent PlanTrak using week-ending 2/3/2017; only considers bridged volume; excludes cash and mail order data; Note: Unrestricted access excludes prior authorisation, step edits and other restrictions LevemirⓇ access based on FlexTouch® Pen; NovoLogⓇ access based on FlexPenⓇ; only considers bridged volume; TresibeⓇ launched in January 2016 Jan 2017 novo nordisk
View entire presentation